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Each year, up to 10,000 cases of infections with the flavivirus tick-borne encephalitis 
(TBE) virus that affect the central nervous system are reported in Europe and Asia. 
Due to the potentially severe adverse effects of post-exposure prophylaxis with TBE 
virus hyperimmunoglobulin, TBE can currently only be treated symptomatically. An 
RNA interference (RNAi) approach to inhibiting TBE virus replication was therefore 
developed. In this study we demonstrate for the first time that small interfering RNAs 
(siRNA) targeted to the TBE virus genome reduce the quantity of infectious TBE virus 
particles, TBE virus genome, and TBE virus protein in vitro by up to 85%. The 50% 
inhibitory dose (DI50]) of the shRNA plasmid was only 0.05 µg/ml. As RNAi-based 
therapeutics for other diseases are already being evaluated in phases II and III 
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DI50; 50% inhibitory dose 
DMEM; Dulbecco's modified Eagle medium 
dsRNA; double stranded RNA 
EGFP; enhanced green fluorescent protein 
GE; genome equivalent 
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HIV; human immunodeficiency virus 
MOI; multiplicity of infection 
PFU; plaque forming units 
RISC; RNA-induced silencing complex 
RNAi; RNA interference 
RT-qPCR; quantitative real-time RT-PCR 
shRNA; short hairpin RNA 
siRNA; small interfering RNA 
TBE; tick-borne encephalitis  
 
1. Introduction 
Viruses of the genus Flavivirus are small enveloped viruses with a single positive-
stranded RNA genome of about 11 kilobases. The genome codes for three structural 
(E, M/preM, and C) and seven non-structural proteins (NS1, NS2a, NS2b, NS3, 
NS4a, NS4b and NS5) (Mansfield et al., 2009). Flaviviruses, transmitted mainly by 
mosquito or tick vectors and a cause of serious health issues throughout the world, 
are divided into three groups: mosquito-borne flaviviruses, tick-borne flaviviruses, and 
flaviviruses with unknown vector (Grard et al., 2007). 
The prototype of tick-borne flaviviruses, tick-borne encephalitis (TBE) virus, is the 
causative agent of TBE that, with an annual average of 10,000 cases, is the most 
important viral encephalitis in Europe and Asia (Süss, 2008). Three mainly human-
pathogenic TBE virus subtypes are known: the European, the Siberian, and the Far 
Eastern subtypes, each associated with varying degrees of disease severity (Grard et 
al., 2007; Gritsun et al., 2003). To date, there is no specific therapy to treat TBE virus 
infection although a vaccine is available (Lindquist and Vapalahti, 2008). Post-
exposure prophylaxis with TBE virus hyperimmunoglobulin is no longer 
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recommended because it can cause adverse events in children and adults and there 
is no evidence for efficacy in adults (Aebi and Schaad, 1994; Noack, 1997; Valdueza 
et al., 1996; Waldvogel et al., 1996). 
The use of RNA interference (RNAi) to regulate gene expression and defend against 
bacterial and viral pathogens is common to all eukaryotic species (Katiyar-Agarwal et 
al., 2006; Navarro et al., 2006). RNAi is induced by double-stranded RNA (dsRNA) 
that in the eukaryotic cell is recognized by an enzyme complex (Dicer) able to cut it 
into pieces of 21 to 23 nucleotides in length (Fire et al., 1998). These fragments, 
known as small interfering RNA (siRNAs), are incorporated into a multi-protein 
complex termed the RNA-induced silencing complex (RISC) that degrades or 
inactivates complementary mRNAs and viral RNAs. 
Although siRNAs can be synthesized chemically and transfected into cells it is also 
possible to clone a synthetic shRNA gene cassette into a plasmid or viral vector for 
subsequent transfection. Such a vector encodes the shRNA that is processed by 
Dicer in the cell into siRNA (Bernstein et al., 2001; Guil and Esteller, 2009; Hajeri and 
Singh, 2009; Hammond et al., 2001; Mathonnet et al., 2007; Stevenson, 2004; 
Valencia-Sanchez et al., 2006). 
Many studies have shown RNAi to be a useful tool for inhibiting replication of viruses 
such as the human immunodeficiency virus (HIV) in vitro or viral hepatitis in vitro and 
in vivo (Coburn and Cullen, 2002; Eekels et al., 2011; Hannon and Rossi, 2004; 
Huang et al., 2010; Jacque et al., 2002; Song et al., 2003; Weinberg and Arbuthnot, 
2010; Zhang et al., 2010). Reduction of virus replication by RNAi in vitro and in vivo 
has also been described for many flaviviruses such as Dengue virus, West Nile virus, 
Japanese encephalitis virus and Yellow fever virus (Bai et al., 2005; Haasnoot and 
Berkhout, 2006; Haasnoot et al., 2007; Haasnoot et al., 2003; Hajeri and Singh, 
2009; Kumar et al., 2006; Murakami et al., 2005; Pacca et al., 2009; Singh and 
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Hajeri, 2009; Stein and Shi, 2008). However, so far no studies describing the effects 
of RNAi on TBE virus infection have been reported. 
We therefore designed and tested in vitro a number of siRNAs targeted to the TBE 
virus genome. The siRNAs were found to reduce the quantity of infectious virus 
particles, viral genomes and virus proteins in cultures of infected cells. 
 
2. Material and Methods 
 
2.1. Virus propagation 
Three cell culture-derived TBE virus strains, one strain for each subtype, were used 
to test the efficacy of the siRNAs: European subtype K23 (GenBank accession no. 
AM600965), Siberian subtype Aina (GenBank accession no. AF091006) and Far 
Eastern subtype Sofjin (GenBank accession no. X03870). Viruses were propagated 
in Vero E6 cells (ATCC CRL-1586) cultivated in Dulbecco's modified Eagle medium 
(DMEM) supplemented with 10% fetal calf serum, 1% glutamine, 1% penicillin and 
1% streptomycin after infection with TBE virus-containing cell culture supernatants at 
a multiplicity of infection (MOI) of 1. Supernatants were harvested after 3 to 5 days 
and the TBE virus titer determined by plaque assay as described below. Unless 
otherwise stated, the TBE virus strain K23 was used as a prototype of all TBE virus 
strains. 
 
2.2. SiRNA target sequence selection and cloning 
Suitable siRNA target sequences in the TBE virus E-protein-coding region (prototype 
strain K23) were identified using the siRNA Target Designer (Promega, Madison, WI, 
USA) and analyzed using the BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
for homology with human and mouse genes. Only sequences that showed a 
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difference to the human or murine genome of more than three base pairs were 
considered. siRNA-targeted sequences were also compared to those of TBE virus 
strains described in the NCBI database (http://blast.ncbi.nlm.nih.gov). SiRNA 
sequences targeting the most conserved viral sequences (no more than two 
mismatches compared to the siRNA target sequences) were selected (Table 1) and 
used to design the corresponding shRNA gene cassettes. 
The shRNA plasmids were produced using the Promega siStrike U6 hairpin cloning 
system kit according to the manufacturer’s instructions. Briefly, the shRNA gene 
cassettes obtained from Invitrogen (Karlsruhe, Germany) were cloned into the 
psiStrike vector using the Promega protocol. Incorporation of the shRNA gene 
cassette into the plasmid was confirmed by a PstI digestion.  
ShRNA plasmids were checked for errors by sequencing. The plasmid SC#1 
containing an shRNA gene cassette based on a randomized siRNA sequence (SC#1) 
was used as negative control.  
 
2.3. Transfection of cells 
5x105 HEK293T cells in 200 µl medium without antibiotics were seeded into each well 
of poly-L-lysine coated (Sigma, Steinheim, Germany) 24-well culture plates one day 
before transfection. Cells were approximately 90% confluent after 24 h. 
Transfection of shRNA plasmids was performed using Lipofectamine 2000 
(Invitrogen, Karlsruhe, Germany) according to the manufacturer’s instructions. Briefly, 
for each well, 1 µg shRNA plasmid and 1 µl Lipofectamine 2000 were diluted in 
200 µl Opti-MEM (Invitrogen, Karlsruhe, Germany), added to the pre-seeded 
HEK293T cells and incubated for 48 h at 37°C and 5% CO2. The transfection 
efficiency was determined by counting the total cell number and the number of cells 





2.4. Infection of cells 
To analyze the effect of the siRNAs on TBE virus infection, HEK293T cells transiently 
transfected with shRNA plasmids, and therefore transiently expressing shRNAs that 
are processed to siRNAs targeted against the TBE virus genome, were infected with 
TBE virus-containing cell culture supernatant. After removing the transfection media, 
200 µl of virus-containing medium were added to each well to give an MOI of 0.1 for 
the K23 and Aina strains and 0.01 for the Sofjin strain. Cells were incubated for 30 
min at 37°C and 5% CO2 before removing the virus-containing medium, washing the 
cells twice with 200 µl of PBS (140 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4) and adding 200 µl fresh medium. After 24 h, 48 h, and/or 72 h of 
incubation, cells were analyzed by immunofluorescence microscopy or harvested to
be further analyzed by RT-qPCR, Western blot and plaque assay. As a negative 
control, cells were transfected with an shRNA plasmid containing an shRNA gene 
cassette based on a nonspecific randomized siRNA sequence (SC#1).  
 
2.5. Isolation of viral nucleic acids 
Total RNA was prepared according to the manufacturer’s instructions from cells and 
cell culture supernatants using the Qiagen RNeasy mini kit (Qiagen, Hilden, 
Germany) or the Qiagen viral extraction kit (Qiagen, Hilden, Germany), respectively. 
To avoid DNA contamination, RNA was also treated with the Turbo DNase Kit 
(Ambion, Foster City, CA, USA) according to the manufacturer’s instructions. 
 
2.6. Virus detection by quantitative real-time RT-PCR 
cDNA was reverse-transcribed from 5 µl RNA in a final reaction volume of 20 µl using 
the Superscript II kit (Invitrogen, Karlsruhe, Germany). The RNA was first incubated 
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for 10 min at 65°C and reverse transcription performed at 37°C for 60 min and at 
93°C for 10 min using a Biometra thermoblock cycler (Biometra, Göttingen, 
Germany). The presence of viral genomes and tubulin genes (as reference) in the 
cDNA was tested by TBE virus-specific quantitative real-time RT-PCR (RT-qPCR) or 
by a tubulin-specific in-house RT-qPCR as described previously (Achazi et al., 2011; 
Radonic et al., 2004). 
 
2.7. Detection of infectious virus particles by plaque assay 
Titers of virus in culture supernatants and cells were determined by plaque assay as 
described by Bae et al. (2003). Culture supernatants were used directly whereas 
cells were first resuspended in 250 µl PBS, frozen and thawed twice (30 min at -
80°C, 30 min at 37°C) and centrifuged for 5 min at 5,000×g to yield supernatants to 
be tested in the plaque assay. 
 
2.8. Isolation of membrane proteins, SDS page, and Western blot 
To isolate membrane proteins from HEK293T cells, culture medium was removed 
and the cells washed twice with 200 µl ice-cold PBS before lysing in 100 µl RIPA 
buffer (150 mM NaCl, 1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 
50 mM Tris, pH 8, 1 mM PMSF, 1% protease inhibitor cocktail III, 25 units / ml 
Benzonase, 1 mM DTT) and centrifugation at 4°C for 10 min at 15,000× g. The 
protein-containing supernatant was then transferred to a new reaction tube for 
storage at -80°C. Protein concentrations were determined using the Invitrogen 
Quant-iT Protein Assay Kit and a Qubit fluorometer (Invitrogen, Karlsruhe, Germany) 
according to the manufacturer’s instructions. 
Protein extracts were subjected to SDS-PAGE and Western blotting as described by 
Muller et al. (2007). Detection of the TBE virus E-protein was used to confirm the 
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presence of virus proteins in the infected cells with β-actin serving as a positive 
control. The murine monoclonal anti-TBE virus antibody MAB 1367 described by 
Niedrig et al. (1994) diluted 1:1,000 was used as first antibody and an HRP-labeled 
anti-mouse immunoglobulin G antibody (Pierce, Rockford, USA, order no. 31450) 
diluted 1:5,000 served as the secondary antibody. The SuperSignal West Femto 
Chemiluminescent system was used for detection (Pierce Biotechnology, Rockford, 
IL, USA) with 1 min exposure of the membrane to the X-ray film. 
 
2.9. Immunofluorescence staining and microscopy 
Immunofluorescence staining was performed as described by Niedrig et al. (1999) 
using MAB 1367 (see above) diluted 1:40 as first antibody and an Alexa 594-labeled 
anti-mouse immunoglobulin G antibody (Invitrogen, Karlsruhe, Germany, order no. 
A11005) diluted 1:500 as secondary antibody. 
Cells were observed using a fluorescence microscope Axioskop 20 (Zeiss, Jena, 
Germany) or a confocal laser scanning microscope cLSM 510 Meta (Zeiss, Jena, 
Germany). 
 
2.10. Statistical analysis 
Laboratory data were handled and analyzed using PASW statistics 17 (version 




3.1. Identification of siRNA target sequences 
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A thorough analysis of all available TBE virus sequences was performed to allow 
development of siRNA molecules binding to the RNA of all three human-pathogenic 
TBE virus subtypes. However, the 15% to 20% diversity between the genomes 
precluded the identification of an siRNA target sequence perfectly fitting all TBE virus 
subtypes. Three siRNA-targeted sequences (Table 1) with no more than one or two 
mismatches to the genome sequences of all TBE virus strains were therefore 
selected. 
Because most sequences available on NCBI are for the E-protein-coding region, the 
selected target sequences are complementary to this region. Furthermore, as the E-
protein is the most important flaviviral structural protein, being responsible for virus 
adherence and absorption, it has been previously targeted by RNAi in studies of 
other flaviviruses (Kumar et al., 2006; Murakami et al., 2005; Pacca et al., 2009). 
 
3.2. Exclusion of aspecific effects on TBE virus infection and transfection 
efficiency 
To exclude potential aspecific effects of shRNA plasmids, the degree of virus 
replication in non-transfected cells was compared to that in cells transfected with the 
control shRNA plasmid SC#1. The quantity of virus was standardized to the amount 
of tubulin expression in the cells.  
The SC#1 control shRNA plasmid had no statistically significant effect (t-test >0.05) 
on the virus genome content of infected cells (data not shown) and was therefore 
used as a negative control in subsequent experiments. 
The transfection efficiency with 5 µg/ml of shRNA plasmid was found to be 47%, 
dropping to 34% with 0.5 µg/ml and 2.5% with 0.05 µg/ml. There was no significant 





3.3. Effects of the siRNAs on a TBE virus infection in cells 
First, cells infected with the TBE virus strain K23 (MOI=0.1) and transfected with the 
shRNA plasmid (5 µg/ml) were sampled every day for 72 h to determine the optimal 
sampling time. siRNA TBEV#2 and TBEV#3 were most effective after one day, 
reducing the virus genome yield by up to 85%. In contrast, siRNA TBEV#1 showed 
the best effect after 72 h with a 65% reduction (Figure 1), although already at 24 h 
inhibition was as high as 58%. In subsequent experiments, the cells were therefore 
harvested 24 h after transfection.  
Different concentrations of shRNA plasmid used to transfect cells (5, 0.5 and 0.05 
µg/ml) were tested to find the optimum and to demonstrate the dose-dependent 
effects of the siRNAs. All three siRNAs significantly reduced the quantity of TBE virus 
genome generated in the cells (t-test <0.05) compared to the control SC#1 (Figure 
1). SiRNA TBEV#2 was most effective (Figure 2) with 0.05 µg/ml being sufficient to 
inhibit the quantity of virus genome by more than 50%, compared to TBEV#3 and 
TBEV#1 that required at least 0.5 µg/ml and 5 µg/ml respectively to achieve the 
same degree of inhibition. 
A plaque assay was used to verify that the RNAi had reduced not only the quantity of 
virus genome but also the number of infectious particles produced (Figure 2). All 
three siRNA tested (TBEV#1, #2, and #3) inhibited the production of infectious 
particles by up to approximately 80%. Although inhibition by the different siRNAs 
varied by about 5%, the siRNAs TBEV#2 and TBEV#3 were again most effective. 
Whether or not shRNA-expressing cells were susceptible to infection was 
investigated by immunofluorescence staining of transfected, TBE virus-infected cells. 
Transfected cells fluoresce green (due to expression of GFP in the shRNA plasmid) 
and an Alexa 594-labeled anti-mouse immunoglobulin G antibody (red) was used to 
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visualise the monoclonal anti-TBE virus antibody bound to virus. Cells that were both 
infected and transfected therefore appeared orange. In addition, cell nuclei were 
stained blue using 4',6-diamidino-2-phenylindole (DAPI).  
TBE virus was present in a proportion of the cells transfected with the control shRNA 
plasmid SC#1. Virus was also observed in cells expressing the siRNA TBEV#1, albeit 
at a lower frequency compared to the control SC#1. In contrast, virus could not be 
detected in any of the cells expressing the shRNA plasmids TBEV#2 or TBEV#3 
(Figure 3A-D). 
Western blot analysis was used to give a semi-quantitative measure of the TBE virus 
E-protein content in shRNA plasmid-treated cells (Figure 4). ShRNA plasmids 
TBEV#2 and TBEV#3 were used as they have  been the most effective against the 
TBE virus strain K23 in previous experiments and β-actin was used as a reference 
protein. 
Although 43 kDa bands for the β-actin protein were present in lysates of non-infected 
and infected cells, the TBE virus E-protein could only be detected in infected cells. 
The intensity of the band from infected cells treated with the control SC#1 was 
stronger than those from shRNA plasmid TBEV#2- and TBEV#3-treated cells, 
indicating an inhibition of E-protein production by the siRNAs. 
 
3.4. Effects of the siRNAs on different TBE virus subtypes 
Finally, we infected cells with three different TBE virus strains, one for each subtype: 
K23 (European), Aina (Siberian), and Sofjin (Far Eastern) to determine the specificity 
of the antiviral effect of the siRNAs. The efficacy of the siRNAs varied according to 
the TBE virus subtype (Figure 5). SiRNA TBEV#1 was most effective for all strains, 
reducing virus content by up to 85%. SiRNA TBEV#3 also reduced virus production 
for all strains observed, although the inhibition was not statistically significant (t-test 
13 
 
>0.05) for the Siberian subtype (strain Aina). Due to mismatches between the 
Siberian and Far Eastern subtypes, siRNA TBEV#2 only inhibited replication of the 
European subtype (strain K23). 
In summary, the results demonstrate that siRNAs targeted against the TBE virus 
genome efficiently reduced the TBE virus load in cell culture with regard to quantity of 
infectious virus particles, viral genome and virus protein. 
 
4. Discussion 
The results of this study demonstrate that siRNAs can inhibit the replication of TBE 
virus in infected cell culture. The efficacy of the three different siRNAs varied 
according to each subtype, which is partly due to mismatches between the siRNA 
and TBE virus strain sequences and possibly also to secondary structures in the 
virus genome that are known to influence the effects (Westerhout and Berkhout, 
2007). SiRNA TBEV#1 exactly matches the TBE virus strains Sofjin (Far Eastern 
subtype) and Aina (Siberian subtype) and most efficiently reduced the yield of virus 
genome for these two strains compared to siRNA TBEV#2 and siRNA TBEV#3. For 
example, siRNA TBEV#1 has two mismatches with TBE virus strain K23 (European 
subtype) and is therefore less inhibitory for this strain. However, some mismatches 
can be tolerated (Amarzguioui and Prydz, 2004; Lin et al., 2003), and indeed the 
siRNA TBEV#3 inhibited the TBE virus strains Aina and Sofjin despite having up to 
two mismatches. 
Complete inhibition of TBE virus by the siRNAs was not achieved with the method 
used here, possibly because cells were only transiently transfected and with an 
average efficiency of only 47% (when using the highest concentration of shRNA 
plasmid). This efficiency is, however, comparable to that reported for other RNAi-
based experiments described in the literature (Wu et al., 2010). 
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siRNAs reduced the yield of virus genome by up to 85% and the production of 
infectious virus particles by 80%. These values are similar to those achieved by 
Pacca et al. (2009) with yellow fever virus and Murakami et al. (2005) with Japanese 
encephalitis virus, who showed a decrease in virus production of between 12% and 
97% depending on the siRNA used. This reduction in virus production in our study 
was also confirmed at the protein level by Western blot analysis. 
Furthermore, similar to the study by Murakami et al. (2005) with Japanese 
encephalitis virus, we showed siRNA to act on TBE virus in a dose-dependent 
manner. The dose of the most efficient siRNA (TBEV#2) required to achieve 50% 
virus inhibition (inhibitory dose [DI50]) of the prototype strain (K23) was 0.05 µg/ml of 
the shRNA plasmid. For the other two shRNA plasmids TBEV#1 and TBEV#3 the 
DI50s were 5 µg/ml and 0.5 µg/ml, respectively. Since high concentrations of siRNAs 
are toxic and could induce non-specific immune responses in vivo, from a medical 
point of view it is important to minimize the amount of siRNA used (Hornung et al., 
2005; Sioud, 2004). SiRNA TBEV# 2 would therefore seem to be the most 
appropriate candidate to serve as a basis for developing antiviral therapies against 
the European subtype, whereas TBEV#1 would be better for all three subtypes. In 
future experiments, all three siRNA could be combined to improve reduction of viral 
replication and to reduce the possibility of TBE virus escape mutants developing.  
The next step will be to test whether the shRNA plasmids are effective when 
administered after the infection of the cells. If successful, the molecules could then be 
tested in vivo (mouse model) to evaluate their efficacy and toxicity. 
The main challenge facing the use of RNAi in living organisms is delivery of the 
siRNAs and plasmid or viral shRNA vectors to their site of action. For the treatment of 
tick-borne encephalitis, the siRNAs or shRNA vectors need to be introduced into the 
brain and different approaches have been developed. In mice, siRNA molecules or 
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even plasmid and viral shRNA vectors can be injected directly into the brain or with 
high pressure into the tail vein (Bai et al., 2005; Harper et al., 2005; Kumar et al., 
2006; Van den Haute et al., 2003) and delivery strategies more appropriate for 
humans have been described in the literature. For example, siRNA molecules can be 
targeted by coupling them to aptamers that bind specifically to certain cell types (Chu 
et al., 2006; McNamara et al., 2006). In addition, modified lentiviral vectors 
expressing specific envelope glycoproteins can be used to transduce cells in the 
CNS, or cell specific promotors can be used to allow cell specific expression. The use 
and safety of the different approaches involving modified lentivirus vectors have 
recently been summarized by Manfredsson and Mandel (2011). A further option to 
introduce siRNA molecules into neural cells is to couple them to a rabies virus 
glycoprotein that passes the blood-brain barrier and binds specifically to neuronal 
cells (Kumar et al., 2007). 
The successful inhibition of virus replication in vivo (mice) has been shown for other 
flaviviruses. Indeed, therapeutic approaches have been developed against many 
other viruses such as hepatitis C virus or HIV and against other diseases such as 
cancer or Alzheimer's disease (Bai et al., 2005; Kumar et al., 2006; Murakami et al., 
2005; Pacca et al., 2009; Ray and Shi, 2006). Finally, RNAi-based drugs against 
human respiratory syncytial virus and age-related macular degeneration have been 
tested in phase II and III clinical trials (Federici et al., 2007; Kim and Rossi, 2007). 
In conclusion, RNAi is a new approach that may develop into a suitable tool for 
controlling TBE virus infection and a therapeutic agent for post-exposure prophylaxis. 
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Table 1: SiRNA target sequences compared to the sequences of the three different 








SC#1a gCggTAgCgCCCATATTAT   
TBEV#1 gggACTggTTCAATgATCT  
K23 (AM600965) gggACTggTTTAATgACCT 1599-1617 
Aina (AF091006) gggACTggTTCAATgATCT 650-668 
Sofjin (X03870) gggACTggTTCAATgATCT 1540-1558 
E-protein 
TBEV#2 ggTCTTACgTACACAATgT  
K23 (AM600965) ggTCTTACgTACACAATgT 1850-1868 
Aina (AF091006) ggTCTCACATACACAATgT 901-919 
Sofjin (X03870) ggTCTTACATACACAATgT 1791-1809 
E-protein 
TBEV#3 gAggTggCTTCATAgAgAT  
K23 (AM600965) gAggTggCTTCATAgAgAT 2052-2070 
Aina (AF091006) gAggAggCTTCATAgAgAT 1103-1121 
Sofjin (X03870) gCggTggCTTCATAgAAAT 1993-2011 
E-protein 
a SC#1, a negative control shRNA plasmid containing a gene cassette based on a 
randomized, scrambled siRNA sequence. Base mismatches in the TBE virus genome 
sequences compared to the siRNA target sequences are underlined. 
 
Figure 1: Time course of TBE virus genome equivalent (GE) copy number in infected 
(strain K23) HEK293T cells transfected with shRNA plasmids TBEV#1, #2, or #3 
compared to HEK293T cells transfected with the control shRNA plasmid SC#1. 

Figure 2: Effects of different shRNA plasmid concentrations on TBE virus plaque-
forming units (PFU, white bars) and TBE virus genome equivalent copy number (GE, 
hatched bars) in HEK293T cells infected with TBE virus (strain K23) at 24h post 
infection. 
All three siRNAs (TBEV#1, #2, and #3) significantly reduced (t-test <0.05) the quantity of 
TBE virus genome compared to the control SC#1. 

Figure 3: Immunofluorescence staining of HEK293T cells infected 24h earlier with TBE 
virus and transfected with shRNA plasmids TBEV#1, #2, and #3. 
Cells are expressing either the control shRNA SC#1 (A), or shRNAs TBEV#1 (B), TBEV#2 
(C), or TBEV#3 (D). Viral proteins are stained red, shRNA-expressing cells fluoresce green, 
and the nuclei are stained blue (DAPI). Cells expressing shRNAs and containing TBE virus 





Figure 4: Effect of siRNAs on the quantity of E-protein in TBE virus (strain K23)-
infected HEK293T cells at 24h post infection. 
Western Blot analysis was performed using lysates from cells transfected with the control 
shRNA plasmid SC#1 or with the most efficient inhibitory plasmids TBEV#2, and TBEV#3.  

Figure 5: Effects of siRNAs TBEV#1, #2, and #3 on different TBE virus subtypes. 
Experiments with every siRNA and strain were performed at least three times in duplicate (5 
times for TBEV strain K23). Standard deviations were calculated for all the experiments and 
replicates. The TBE virus genome equivalent (GE) copy number was normalized to the 
reference gene tubulin at 24h post infection. Statistically significant differences (t-test p < 
0.05) are marked with an asterisk. 

>We developed small interfering RNAs (siRNA) targeted to the TBE virus genome. 
>siRNAs reduce the quantity of TBE virus particles, genome, and protein up to 85%. 
>The 50% inhibitory dose of the shRNA plasmid was 0.05 µg/ml. >RNA interference 
could become valuable tool for controlling TBE virus infections. 
